

Rule 1.53(b) Cont. Appln.
of Serial No. 08/465,712

IN THE CLAIMS:

Please cancel claims 1-39.

Please add the following new claims.

B2 Cont
Sub A
--40. A transgenic mouse all of whose germ cells and somatic cells contain a DNA sequence comprising a promoter of the $\beta 2$ -subunit of neuronal nicotinic acetylcholine receptor having the sequence from about nucleotide -1125 to about nucleotide +38 as set forth in Figure 1 (SEQ ID NO. 22) operatively linked to a nucleotide sequence encoding a heterologous polypeptide, wherein the heterologous polypeptide is a toxin, a growth factor, or an oncogenic, tumorigenic, or immortalizing protein, and is expressed in neurons of the transgenic mouse, and wherein the DNA sequence was introduced into the transgenic mouse or an ancestor of the transgenic mouse at an embryonic stage.

41. A transgenic mouse generated by crossing a first mouse with a second mouse, wherein all of the germ cells and somatic cells of the first mouse contain a DNA sequence comprising a promoter of the $\beta 2$ -subunit of neuronal nicotinic acetylcholine receptor having the sequence from about nucleotide -1125 to about nucleotide +38 as set forth in Figure 1 (SEQ ID NO. 22) operatively linked to a nucleotide sequence encoding a heterologous polypeptide,

Rule 1.53(b) Cont. Appln.
of Serial No. 08/465,712

02 Cont
wherein the heterologous polypeptide is expressed in neurons
of the first mouse, wherein the DNA was introduced into the
first mouse or an ancestor of the first mouse at an
embryonic stage, and wherein the neurons of the transgenic
mouse express the heterologous polypeptide.

42. A transgenic mouse as claimed in claim 41, wherein
the second mouse belongs to the same species as the first
mouse.

43. A transgenic mouse as claimed in claim 42, wherein
the DNA of the second mouse is not identical to the DNA of
the first mouse.

44. A transgenic mouse as claimed in claim 43, wherein
the second mouse is a transgenic mouse containing a
different transgene than the first mouse.

45. A transgenic mouse as claimed in claim 43, wherein
the second mouse contains a naturally occurring mutation not
present in the first mouse.

Sub E³ 46. A process for producing a neuronal host cell that
expresses a heterologous protein, comprising transferring to
the neuronal host cell a DNA sequence comprising a promoter
of the $\beta 2$ -subunit of neuronal nicotinic acetylcholine
receptor having the sequence from about nucleotide -1125 to
about nucleotide +38 as set forth in Figure 1 (SEQ ID NO.

Rule 1.53(b) Cont. Appln.
of Serial No. 08/465,712

22) operatively linked to a nucleotide sequence encoding the heterologous polypeptide under suitable conditions to cause expression of the heterologous polypeptide by the neuronal host cell.

47. The process according to claim 46, wherein the heterologous polypeptide is a toxin, a growth factor, or an oncogenic, tumorigenic, or immortalizing protein.--

REMARKS

Claims 40-47 are pending in this application. Applicants have canceled claims 1-39. Applicants have added claims 40-47.

Support for claim 40 can be found throughout the specification, including, for example, page 13, lines 14-25. Support for claims 41-47 can be found throughout the specification, including, for example, the paragraph spanning pages 8 and 9 and the paragraph spanning pages 9 and 10. Accordingly, no new matter has been added.

Applicants have also inserted Table 1, as originally filed, into the specification at page 43. Accordingly, lines 5-18 of page 21, which describe the contents of Table 1, have been deleted and reinserted at page 43 following the Table.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000